Danila Valmori

Summary

Country: France

Publications

  1. ncbi Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors
    Danila Valmori
    Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Lutte Contre le Cancer René Gauducheau, 44800 Saint Herblain, France
    Proc Natl Acad Sci U S A 107:19402-7. 2010
  2. ncbi Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:8947-52. 2007
  3. ncbi Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals
    Emmanuelle Godefroy
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Cancer Immunol Immunother 56:1183-92. 2007
  4. ncbi CD4+ T cell responses to SSX-4 in melanoma patients
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Immunol 174:5092-9. 2005
  5. ncbi Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Immunol 114:70-8. 2005
  6. ncbi Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire
    Gilles Bioley
    Institut National de la Sante et de la Recherche Medicale, CLCC Rene Gauducheau, Boulevard Jacques Monod, Saint Herblain, France
    Clin Cancer Res 15:4467-74. 2009
  7. ncbi Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center and Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Immunol 172:7206-11. 2004
  8. ncbi Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers
    Maha Ayyoub
    Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Lutte Contre le Cancer René Gauducheau, 44800 Saint Herblain, France
    Proc Natl Acad Sci U S A 107:7437-42. 2010
  9. ncbi HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine
    Gilles Bioley
    Institut National de la Sante et de la Recherche Medicale, U892, CLCC Rene Gauducheau, Saint Herblain, France
    Clin Cancer Res 15:299-306. 2009
  10. ncbi Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
    Clin Immunol 122:163-72. 2007

Collaborators

Detail Information

Publications62

  1. ncbi Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors
    Danila Valmori
    Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Lutte Contre le Cancer René Gauducheau, 44800 Saint Herblain, France
    Proc Natl Acad Sci U S A 107:19402-7. 2010
    ..Together our results support the concept that priming of human T(H)17 from naive CD4(+) T cells preferentially takes place from FOXP3(+) Treg precursors in the presence of lineage-specific polarizing factors...
  2. ncbi Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:8947-52. 2007
    ....
  3. ncbi Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals
    Emmanuelle Godefroy
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Cancer Immunol Immunother 56:1183-92. 2007
    ....
  4. ncbi CD4+ T cell responses to SSX-4 in melanoma patients
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Immunol 174:5092-9. 2005
    ....
  5. ncbi Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Immunol 114:70-8. 2005
    ..Retrieval of multiple overlapping epitopes in a defined region of SSX-2 protein suggests the presence of a "hot spot" for T cell recognition that may prove sufficient for the induction of immune responses...
  6. ncbi Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire
    Gilles Bioley
    Institut National de la Sante et de la Recherche Medicale, CLCC Rene Gauducheau, Boulevard Jacques Monod, Saint Herblain, France
    Clin Cancer Res 15:4467-74. 2009
    ..The purpose of the present study was to characterize vaccine-induced ESO-specific CD4(+) T cell responses...
  7. ncbi Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center and Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Immunol 172:7206-11. 2004
    ..In contrast, it was efficiently presented by autologous dendritic cells, supporting the concept that processing by professional APC is the main pathway through which the CD4(+) T cell immunoresponse to tumor Ags occurs in vivo...
  8. ncbi Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers
    Maha Ayyoub
    Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Lutte Contre le Cancer René Gauducheau, 44800 Saint Herblain, France
    Proc Natl Acad Sci U S A 107:7437-42. 2010
    ..This approach may significantly accelerate the development of reliable MHC class II tetramers to monitor immune responses to tumor and self-antigens...
  9. ncbi HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine
    Gilles Bioley
    Institut National de la Sante et de la Recherche Medicale, U892, CLCC Rene Gauducheau, Saint Herblain, France
    Clin Cancer Res 15:299-306. 2009
    ..Vaccine-induced CTL mostly recognized a single immunodominant region (ESO 81-110). The purpose of the present study was to identify genetic factor(s) distinguishing CTL responders from nonresponders...
  10. ncbi Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
    Clin Immunol 122:163-72. 2007
    ..Our results support the concept that epitope clustering within defined protein regions identifies tumor antigen immunodominant regions and suggest a general strategy for their identification...
  11. ncbi Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles
    Emmanuelle Godefroy
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
    Clin Immunol 121:54-62. 2006
    ..Identification of these epitopes will be instrumental for the evaluation of the immune response to Melan-A in cancer patients...
  12. ncbi IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
    Mitsutoshi Matsuo
    Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:14467-72. 2004
    ..This model of conditional cross-presentation establishes an original level of action for IFN-gamma as an effective immune modulator and supports the use of IFN-gamma in protein vaccination strategies targeting LCs...
  13. ncbi A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Immunol 118:188-94. 2006
    ..We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens...
  14. ncbi Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
    Clin Immunol 117:161-7. 2005
    ..In contrast, no reactivity was found against the amino-terminal part of the protein, which was concomitant with the paucity, in this region, of sequences with predicted high binding to MHC class II molecules...
  15. ncbi CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity
    Nassima Redjimi
    Institut National de la Sante et de la Recherche Medicale, institut de cancérologie de l Ouest, Nantes Saint Herblain, France
    Cancer Res 72:4351-60. 2012
    ..Together, our findings support the concept that natural CXCR3(+) T-bet(+) Treg selectively accumulate in ovarian tumors to control type I T-cell responses, resulting in the collateral limitation of efficient antitumor immunity...
  16. ncbi Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers
    Maha Ayyoub
    Institut National de Santé et de Recherche Médicale, Unite 892, CLCC Rene Gauducheau, Saint Herblain, France
    Clin Cancer Res 16:4607-15. 2010
    ..In this study, we generated DRB1*0101/ESO(119-143) tetramers and used them to assess CD4 T-cell responses in vaccinated patients expressing DRB1*0101 (DR1)...
  17. ncbi The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Cancer Immun 4:7. 2004
    ..Together, these findings strongly support the implementation of CTA-based immunotherapy of sarcoma as a means to improve the efficacy of the standard therapy...
  18. ncbi Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Clin Cancer Res 12:398-404. 2006
    ....
  19. ncbi Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Department of Medicine, Columbia University College of Physicians and Surgeons, Black Building 20 09, 650 West 168th Street, New York, NY 10032, USA
    J Immunol 177:944-9. 2006
    ..This condition, however, is temporary and reversible as it is dependent upon the continuous presence of rapamycin...
  20. ncbi Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo
    Ahmed Hamai
    Institut National de la Sante et de la Recherche Medicale, Unité 1102, institut de cancérologie de l Ouest, Saint Herblain, France
    Cancer Res 72:1059-63. 2012
    ....
  21. ncbi Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Immunol 117:24-30. 2005
    ....
  22. ncbi Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells
    Lucie Leveque
    Institut National de la Sante et de la Recherche Medicale, CLCC Rene Gauducheau, Saint Herblain section signFaculty of Medicine, University of Nantes, Nantes, France
    J Immunother 32:101-8. 2009
    ....
  23. ncbi An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Clin Invest 113:1225-33. 2004
    ....
  24. ncbi Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t
    Maha Ayyoub
    Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre Rene Gauducheau, 44800 Saint Herblain, France
    Proc Natl Acad Sci U S A 106:8635-40. 2009
    ....
  25. ncbi NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment
    Nassima Redjimi
    Institut National de la Sante et de la Recherche Medicale, Unite 892, CLCC Rene Gauducheau, Saint Herblain, France
    PLoS ONE 6:e22845. 2011
    ..Their relatively low frequency and advanced differentiation stage, however, may limit their efficacy, that may be boosted by immunogenic ESO vaccines...
  26. ncbi Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs
    Valeria Tosello
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Immunol 126:291-302. 2008
    ..Our data suggest that a division of labor between CM and EM Tregs ensures tolerance at lymphoid and peripheral locations including tumor sites...
  27. ncbi IL-1beta and IL-2 convert human Treg into T(H)17 cells
    Florence Deknuydt
    Institut National de la Sante et de la Recherche Medicale, Unite 892, CLCC Rene Gauducheau, Saint Herblain, France
    Clin Immunol 131:298-307. 2009
    ..Our results indicate that, under inflammatory conditions, in the presence of IL-2, Treg can be converted into pro-inflammatory T(H)17 cells and establish a functional link between inflammation and autoimmunity...
  28. ncbi Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:1191-6. 2003
    ..e., HLA eligibility criteria and knowledge of epitope, while allowing for facilitated immunogenicity in the presence of helper epitopes...
  29. ncbi SSX antigens as tumor vaccine targets in human sarcoma
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Cancer Immun 3:13. 2003
    ..The results of this study indicate that SSX antigens are relevant targets for the development of vaccine-based immunotherapy of sarcoma and encourage the start of vaccination trials using SSX-derived immunogens in sarcoma patients...
  30. ncbi Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells
    Caroline Raffin
    INSERM, Unite 892, Centre de Lutte Contre le Cancer René Gauducheau, 44800 Saint Herblain, France
    J Immunol 187:5196-202. 2011
    ....
  31. ncbi Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
    Valerie Dutoit
    Ludwig Institute Clinical Trial Center, New York Branch at Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 110:1813-22. 2002
    ....
  32. ncbi A peripheral circulating compartment of natural naive CD4 Tregs
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Clin Invest 115:1953-62. 2005
    ..The definition of this subset has important implications for the analysis of human naturally occurring Tregs and for their targeting in therapeutic immune interventions...
  33. ncbi Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy
    Ahmed Hamai
    Institut National de la Sante et de la Recherche Medicale, Unite 892, CLCC Rene Gauducheau, Saint Herblain, France
    PLoS ONE 6:e21129. 2011
    ....
  34. ncbi Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York, USA
    PLoS Med 1:e26. 2004
  35. ncbi Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
    Yasuhiro Nagata
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:10629-34. 2002
    ..These results indicate that monocyte-derived DCs will be easier to load by using protein antigen in vitro than CD34-derived DCs, and that the latter population exhibits a restricted ability to crosspresent soluble exogenous antigens...
  36. ncbi Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity
    Danila Valmori
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, and Multidisciplinary Oncology Center, University Hospital, Lausanne, Switzerland
    J Immunol 168:4231-40. 2002
    ..Collectively, these data show that tumor peptide-driven immune stimulation leads to the selection of high-avidity T cell clones of increased tumor reactivity that independently evolve within oligoclonal populations...
  37. ncbi Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo
    Javier Garcia Casado
    Ludwig Institute for Cancer Research Lausanne Branch, University of Lausanne, Chemin des Boveresses 155, Epalinges, Switzerland
    Eur J Immunol 38:1867-76. 2008
    ..The induced CD4+ T cells were primarily directed against a single NY-ESO-1 epitope spanning amino acids 81-100. Altogether, our study shows that rLV/ESO induces potent and comprehensive immune responses in vivo...
  38. ncbi Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine
    Danila Valmori
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
    Cancer Immun 3:15. 2003
    ....
  39. ncbi Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors
    Frederique Anne Le Gal
    Laboratory of Tumor Immunology, Division of Oncology, Department of Internal Medicine, University Hospital, Geneva, Switzerland
    J Invest Dermatol 127:622-9. 2007
    ..Focusing research on patients with favorable outcomes may help to identify parameters that are crucial for an efficient antitumor response and to optimize cancer immunotherapy...
  40. ncbi Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
    Elke Jager
    Ludwig Institute Clinical Trial Center, Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, Steinbacher Hohl 2 26, 60488 Frankfurt, Germany
    Proc Natl Acad Sci U S A 103:14453-8. 2006
    ..In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination...
  41. ncbi Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1
    Maha Ayyoub
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, CH-1005 Lausanne, Switzerland
    Clin Cancer Res 9:669-77. 2003
    ..CONCLUSIONS: Patient immunization with the analog peptide leads to in vivo activation of T cells that were specific for the natural tumor antigen, demonstrating the usefulness of the analog peptide for melanoma immunotherapy...
  42. ncbi Melan-A/MART-1-specific CD8 T cells: from thymus to tumor
    Mikael J Pittet
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
    Trends Immunol 23:325-8. 2002
  43. ncbi Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate
    Valerie Dutoit
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunol 170:5110-7. 2003
    ..As a consequence of these molecular interactions, under physiologic conditions CD8 plays a key role in complex formation, resulting in the enhancement of CD8 T cell functions whose specificity, however, is determined by the TCR...
  44. ncbi Thymic selection generates a large T cell pool recognizing a self-peptide in humans
    Alfred Zippelius
    Division of Clinical Onco Immunology, University Hospital CHUV, 1011 Lausanne, Switzerland
    J Exp Med 195:485-94. 2002
    ..This represents the only known naive self-peptide-specific T cell repertoire directly accessible in humans...
  45. ncbi Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR
    Valerie Dutoit
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Hopital Orthopedique, Niveau 5, Avenue Pierre Decker 4, CH 1005 Lausanne, Switzerland
    J Immunol 168:1167-71. 2002
    ..These findings are relevant for both identification and isolation of tumor-reactive CTL...
  46. ncbi Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity
    Danila Valmori
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, 1005 Lausanne, Switzerland
    Cancer Res 62:1743-50. 2002
    ..Overall, these results provide the first evidence that a proportion of melanoma patients have circulating tumor-reactive T cells, which are lytic effectors cells...
  47. ncbi Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma
    Maha Ayyoub
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    J Immunol 168:1717-22. 2002
    ....
  48. ncbi Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells
    Seiya Susumu
    Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1 7 1 Sakamoto, Nagasaki 852 8501, Japan
    Cancer Sci 99:107-12. 2008
    ..These results suggest that the hsc70-ESO p157-165 fusion protein is therefore considered to be a promising candidate as a cancer vaccine...
  49. ncbi Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition
    Valerie Dutoit
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
    Cancer Immun 2:7. 2002
    ..However, as the cross-reactivity of these apparently peptide-specific allorestricted TCRs is presently unpredictable, a careful in vitro analysis of their reactivity to the host's normal cells is recommended...
  50. ncbi Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen
    Pierre Yves Dietrich
    Division of Oncology, Laboratory of Tumor Immunology, University Hospital, Geneva, Switzerland
    J Immunol 170:5103-9. 2003
    ..1-bearing TCRs, whereas functional outcomes result from the sum of these with other interactions between pMHC complex and TCR...
  51. ncbi Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells
    Laurence Chapatte
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland
    J Immunol 173:6033-40. 2004
    ....
  52. ncbi Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes
    Valerie Dutoit
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, Lausanne, Switzerland
    Eur J Immunol 32:3285-93. 2002
    ....
  53. ncbi Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1
    Frederique Anne Le Gal
    Division of Oncology, Laboratory of Tumor Immunology, University Hospital, Geneva, Switzerland
    J Immunother 28:252-7. 2005
    ..Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity...
  54. ncbi Tinkering with nature: the tale of optimizing peptide based cancer vaccines
    Olivier Michielin
    Office of Information Technology, Ludwig Institute for Cancer Research, Epalinges, Switzerland
    Cancer Treat Res 123:267-91. 2005
  55. ncbi Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma
    Pedro Romero
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
    Immunol Rev 188:81-96. 2002
    ....
  56. ncbi Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses
    Laurence Chapatte
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
    Cancer Res 66:5461-8. 2006
    ..These results suggest that the inefficient processing of self-antigens, such as Melan-A, by the immunoproteasomes of professional antigen-presenting cells prevents the induction of antitumor T-cell responses in vivo...
  57. ncbi Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL
    Verena Rubio-Godoy
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Lausanne, Switzerland
    J Immunol 169:5696-707. 2002
    ..Together, these results underline the high predictive value of PS-SCL for the identification of sequences cross-recognized by Ag-specific T cells...
  58. ncbi Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content
    Sheng-Wei Ye
    Department of Colorectal Surgery, Peking University School of Oncology, Beijing Cancer Hospital, No. 52 Fu-cheng Road, Hai-Dian District, Beijing 100036, PR China
    J Clin Immunol 26:447-56. 2006
    ....
  59. ncbi Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity
    Verena Rubio-Godoy
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital (CHUV, Lausanne, Switzerland
    Eur J Immunol 32:2292-9. 2002
    ..These results underline the high predictive value of positional scanning synthetic combinatorial peptide library analysis and encourage its use for the identification of CTL ligands...
  60. ncbi Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans
    Valerie Dutoit
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital CHUV, 1011 Lausanne, Switzerland
    J Exp Med 196:207-16. 2002
    ..Altogether these results indicate that the high frequency of Melan-A multimer(+) T cells can be explained by the existence of largely cross-reactive subsets of naive CD8(+) T cells displaying multiple specificities...
  61. ncbi Therapeutic cancer vaccines based on molecularly defined human tumor antigens
    Pedro Romero
    Divison of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Avenue Pierre Decker 4, 1005 Lausanne, Switzerland
    Vaccine 20:A2-7. 2002
    ..Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites...
  62. ncbi Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients
    Maha Ayyoub
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland
    Cancer Res 63:5601-6. 2003
    ....